Kyverna Therapeutics, Inc. (KYTX)
Automate Your Wheel Strategy on KYTX
With Tiblio's Option Bot, you can configure your own wheel strategy including KYTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KYTX
- Rev/Share 0.0
- Book/Share 5.1835
- PB 0.7775
- Debt/Equity 0.031
- CurrentRatio 7.4388
- ROIC -0.6956
- MktCap 174172054.0
- FreeCF/Share -3.1309
- PFCF -1.2873
- PE -1.1976
- Debt/Assets 0.0266
- DivYield 0
- ROE -0.5162
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 5
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | KYTX | H.C. Wainwright | Neutral | Buy | -- | $5 | May 27, 2025 |
| Initiation | KYTX | UBS | -- | Buy | -- | $13 | Oct. 10, 2024 |
| Initiation | KYTX | Rodman & Renshaw | -- | Buy | -- | $16 | Oct. 9, 2024 |
News
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Published: July 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf of long-term stockholders following a class action complaint that was filed against Kyverna on December 9, 2024 with a Class Period pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering (“IPO”) conducted on February 8, 2024. Our investigation concerns whether the board of directors of Kyverna have breached their fiduciary duties to the company.
Read More
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf of long-term stockholders following a class action complaint that was filed against Kyverna on December 9, 2024 with a Class Period pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering (“IPO”) conducted on February 8, 2024. Our investigation concerns whether the board of directors of Kyverna have breached their fiduciary duties to the company.
Read More
Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025
Published: March 21, 2025 by: Seeking Alpha
Sentiment: Positive
Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half of 2025. The global Myasthenia Gravis market is expected to generate sales of $6.7 billion by 2032. Release of topline data from phase 2 KYSA-8 study, using KYV-101 for the treatment of patients with Stiff Person Syndrome, expected in 1st half of 2026.
Read More
About Kyverna Therapeutics, Inc. (KYTX)
- IPO Date 2024-02-09
- Website https://kyvernatx.com
- Industry Biotechnology
- CEO Warner Biddle
- Employees 112